GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (MEX:PRQR) » Definitions » Cyclically Adjusted Price-to-FCF

ProQR Therapeutics NV (MEX:PRQR) Cyclically Adjusted Price-to-FCF : (As of Jun. 22, 2024)


View and export this data going back to 2019. Start your Free Trial

What is ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ProQR Therapeutics NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF falls into.



ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ProQR Therapeutics NV's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ProQR Therapeutics NV's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.508/128.5800*128.5800
=-3.508

Current CPI (Mar. 2024) = 128.5800.

ProQR Therapeutics NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -2.803 99.240 -3.632
201409 -10.147 99.960 -13.052
201412 -4.380 99.050 -5.686
201503 -3.900 99.750 -5.027
201506 -4.901 100.230 -6.287
201509 -5.134 100.500 -6.568
201512 -5.598 99.730 -7.217
201603 -6.790 100.310 -8.704
201606 -8.817 100.260 -11.307
201609 -10.424 100.570 -13.327
201612 -6.865 100.710 -8.765
201703 -7.574 101.440 -9.600
201706 -8.375 101.370 -10.623
201709 -6.524 102.030 -8.222
201712 -7.058 101.970 -8.900
201803 -6.817 102.470 -8.554
201806 -4.031 103.100 -5.027
201809 -2.850 103.950 -3.525
201812 -5.244 103.970 -6.485
201903 -7.095 105.370 -8.658
201906 -6.116 105.840 -7.430
201909 -4.919 106.700 -5.928
201912 -5.387 106.800 -6.486
202003 -7.894 106.850 -9.499
202006 -5.628 107.510 -6.731
202009 -5.228 107.880 -6.231
202012 -5.725 107.850 -6.825
202103 -5.648 108.870 -6.671
202106 -3.637 109.670 -4.264
202109 -2.917 110.790 -3.385
202112 1.157 114.010 1.305
202203 -6.365 119.460 -6.851
202206 -4.492 119.050 -4.852
202209 -4.355 126.890 -4.413
202212 -5.079 124.940 -5.227
202303 10.638 124.720 10.967
202306 -2.442 125.830 -2.495
202309 -1.801 127.160 -1.821
202312 -1.350 126.450 -1.373
202403 -3.508 128.580 -3.508

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProQR Therapeutics NV  (MEX:PRQR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV (MEX:PRQR) Business Description

Industry
Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

ProQR Therapeutics NV (MEX:PRQR) Headlines